<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="144505">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01767285</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00030001</org_study_id>
    <nct_id>NCT01767285</nct_id>
  </id_info>
  <brief_title>Immediate vs. Delayed Postpartum Etonogestrel Implant</brief_title>
  <official_title>A Randomized Controlled Trial of Immediate Postpartum Etonogestrel Implant Versus Six-week Postpartum Etonogestrel Implant: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators are examining if there is a difference in continuation rates of the
      etonogestrel contraceptive implant between women who have the device placed immediately
      after delivery, before leaving the hospital, and women who have the device placed at the
      routine 6-week postpartum visit. There will be 60 subjects total, randomized in a 1:1 ratio,
      for 30 in each group. All participants will follow-up at the same postpartum clinic 6 weeks
      after delivery. They will then be contacted at 3, 6, and 12 months postpartum and asked to
      complete a brief survey. The investigators hypothesize that continuation rates of Implanon
      will be higher in the immediate postpartum placement arm than in the delayed placement arm.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Continuation rate</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify a difference in continuation rates of Implanon® between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of intercourse</measure>
    <time_frame>6 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify differences in the rates of intercourse prior to the 6-week postpartum visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation Rate</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify a difference in continuation rates of Implanon® at one year between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Continuation Rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify a difference in continuation rates of Implanon® between women who have the device placed immediately postpartum and women who have the device placed at the 6-week postpartum visit.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Continuation of breastfeeding</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify differences in continuation of breast-feeding at 6 months between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pregnancy Rate</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify differences pregnancy rates between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
  </other_outcome>
  <other_outcome>
    <measure>patient satisfaction</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>To identify differences in satisfaction with birth control method between women who have immediate versus delayed (6 weeks) postpartum Implanon® placement.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Continuation Rate of Contraceptive Implant</condition>
  <arm_group>
    <arm_group_label>Immediate Postpartum Etonogestrel Implant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Etonogestrel implant placed in the hospital after delivery, before discharge home.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed postpartum etonogestrel implant</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>These subjects will have the etonogestrel implant placed at the 6 week postpartum visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etonogestrel implant</intervention_name>
    <description>This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.</description>
    <arm_group_label>Immediate Postpartum Etonogestrel Implant</arm_group_label>
    <arm_group_label>Delayed postpartum etonogestrel implant</arm_group_label>
    <other_name>Implanon</other_name>
    <other_name>Nexplanon</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1)Age 12-40 years 2)Must deliver at Duke Hospital 3)Must have a working telephone number
        4)No contraindications to receiving this method of contraception, which include: known or
        suspected pregnancy, active liver disease or hepatic tumor, current or past history of
        thrombosis or thromboembolic disorder, undiagnosed abnormal genital bleeding, known or
        suspected breast cancer or history of breast cancer, hypersensitivity to any of the
        components of the device.

        -

        Exclusion Criteria:

          1. Not meeting inclusion criteria

          2. Use of chronic medical therapy that has an adverse interaction with etonogestrel.
             Medications that will be cause for exclusion from the study include:

        1. Non-nucleoside reverse transcriptase inhibitors 2. ritonavir-boosted protease
        inhibitors 3. Certain anticonvulsants - phenytoin, carbamazepine, barbiturates, primidone,
        topiramate, oxcarbazepine 4. Rifampin 5. St. John's Wort

        -
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jessica Morse, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Hospital Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Finer LB, Henshaw SK. Disparities in rates of unintended pregnancy in the United States, 1994 and 2001. Perspect Sex Reprod Health. 2006 Jun;38(2):90-6.</citation>
    <PMID>16772190</PMID>
  </reference>
  <reference>
    <citation>Espey E, Ogburn T. Long-acting reversible contraceptives: intrauterine devices and the contraceptive implant. Obstet Gynecol. 2011 Mar;117(3):705-19. doi: 10.1097/AOG.0b013e31820ce2f0. Review.</citation>
    <PMID>21343774</PMID>
  </reference>
  <reference>
    <citation>Guazzelli CA, de Queiroz FT, Barbieri M, Torloni MR, de Araujo FF. Etonogestrel implant in postpartum adolescents: bleeding pattern, efficacy and discontinuation rate. Contraception. 2010 Sep;82(3):256-9. doi: 10.1016/j.contraception.2010.02.010. Epub 2010 Mar 29.</citation>
    <PMID>20705154</PMID>
  </reference>
  <reference>
    <citation>Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception. 2010 May;81(5):421-6. doi: 10.1016/j.contraception.2009.12.006. Epub 2010 Jan 15.</citation>
    <PMID>20399949</PMID>
  </reference>
  <reference>
    <citation>Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod. 1999 Apr;14(4):976-81.</citation>
    <PMID>10221230</PMID>
  </reference>
  <reference>
    <citation>Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, Zampaglione E; Implanon US Study Group. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception. 2005 May;71(5):319-26.</citation>
    <PMID>15854630</PMID>
  </reference>
  <reference>
    <citation>Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception. 2009 Dec;80(6):519-26. doi: 10.1016/j.contraception.2009.05.124. Epub 2009 Jul 10.</citation>
    <PMID>19913145</PMID>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 30, 2013</lastchanged_date>
  <firstreceived_date>January 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Etonogestrel Implant</keyword>
  <keyword>Implanon</keyword>
  <keyword>Nexplanon</keyword>
  <keyword>Long Acting Reversible Contraception</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-keto-desogestrel</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
